Competition.
Excerpt from May conference call. Of course listen to/read safe harbor statements preceding all CC's.
Unidentified Analyst
Okay, Mark, can you discuss the competition out there and with regard to that, what kind of patent protection do you have? Maybe discuss the strongest patents that you think you have and what kind of expiration dates these patents have? I mean, you have been doing this for a while, and ultimately someone, Dyadic or somebody else is going to want to – if this is successful proof of concept, is going to want to take this to the next step and start trials and go to the FDA and all that stuff takes a lot of time. So I’m just wondering what kind of patent protection you have and what kind of competitions is out there?
Mark Emalfarb
Yes, the competition, let’s address it first. A lot of competition in bacteria, yeast, CHO cells, so different levels of competition. Certain cell lines like bacteria can’t make glycoproteins at least naturally, so there is a variety of other expression systems out there. We did believe that C1 has the attributes and the properties that puts it to the top of the class and gives people the confidence that with the synthetic biology and the genomics and OMICS or the other tools that are out there today and getting better, quicker, faster and cheaper, it can be applied as cell line, that’s been proven industrially to be productive, robust and versatile and scalable, and this is the cell line you want to work with to get to the future.
(Cho cells from Chinese Hamster Ovaries are used in some of the best selling monoclonal antibodies such as Rituxan, Humira and Enbrel)
